{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T18:13:44Z","timestamp":1792260824715,"version":"4.4.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Breast cancer (BC) and ovarian cancer (OC) are leading causes of cancer-related mortality among women worldwide. Despite their distinct clinical presentation these malignancies share genetic, hormonal, and micro-environmental characteristics, suggesting overlapping mechanisms of tumorigenesis and immune escape. Identifying common immune-related biomarkers could improve large scale early detection and guide the development of shared therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a multiplex immunoassay profiling of 81 immune-related proteins including cytokines, chemokines, growth factors, and immune checkpoints in serum samples from 57 BC patients, 57 OC patients, and 49 healthy controls (HC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Multivariate and univariate analyses were utilized to identify proteins exhibiting significant dysregulation. Receiver Operating Characteristic (ROC) curve analyses were conducted to evaluate the diagnostic performance of individual and combined protein panels. Protein-protein interaction networks were constructed using STRING and Cytoscape to elucidate shared functional modules. Multivariate analysis revealed a partial yet significant distinction between cancer patients and HC, with BC and OC exhibiting notable immunological similarities. Eighteen proteins were dysregulated in BC and OC as compared to HC, indicating shared oncogenic and immunological pathways. Furthermore, individual biomarkers exhibited moderate diagnostic performance, while combined panels achieved high accuracy. Network analysis revealed highly interconnected modules centered on the TNF\/TNFR superfamily, co-stimulatory molecules, and chemokines, suggesting promising targets for combinatorial immunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Disscussion<\/jats:title>\n                    <jats:p>our findings demonstrate a significant overlap in immune-related protein expression between BC and OC, supporting the feasibility of a common diagnostic biomarker panel for these female cancers. The identified proteins and their interaction networks offer valuable insights into the shared mechanisms of tumor progression and immune evasion, presenting promising avenues for early diagnosis and targeted therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1741582","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:28:11Z","timestamp":1773923291000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Breast and ovarian cancers: toward a multi-cancer early detection test"],"prefix":"10.3389","volume":"17","author":[{"given":"Azza","family":"Habel","sequence":"first","affiliation":[{"name":"Laboratory of Mycology, Pathologies, and Biomarkers (LR16ES05), Faculty of Sciences of Tunis, University of Tunis El Manar","place":["Tunis, Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryem","family":"Bessaad","sequence":"additional","affiliation":[{"name":"Laboratory of Mycology, Pathologies, and Biomarkers (LR16ES05), Faculty of Sciences of Tunis, University of Tunis El Manar","place":["Tunis, Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouna","family":"stayoussef","sequence":"additional","affiliation":[{"name":"Laboratory of Mycology, Pathologies, and Biomarkers (LR16ES05), Faculty of Sciences of Tunis, University of Tunis El Manar","place":["Tunis, Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weili","family":"Xu","sequence":"additional","affiliation":[{"name":"Singapore Immunology Network (SIgN), Agency for Science Technology and Research (A*STAR)","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanen","family":"Bouaziz","sequence":"additional","affiliation":[{"name":"Salah Azaiez Oncology Institute","place":["Tunis, Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouna","family":"Ayadi","sequence":"additional","affiliation":[{"name":"Salah Azaiez Oncology Institute","place":["Tunis, Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anis","family":"Larbi","sequence":"additional","affiliation":[{"name":"Singapore Immunology Network (SIgN), Agency for Science Technology and Research (A*STAR)","place":["Singapore, Singapore"]},{"name":"Beckman Coulter Life Sciences","place":["Villepinte, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basma","family":"Yaacoubi-Loueslati","sequence":"additional","affiliation":[{"name":"Laboratory of Mycology, Pathologies, and Biomarkers (LR16ES05), Faculty of Sciences of Tunis, University of Tunis El Manar","place":["Tunis, Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"B1","unstructured":"Cancer incidence and mortality worldwide \u2014 Donn\u00e9es globales sur le cancer de l\u2019ovaire"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.5772\/59682","article-title":"Relationship of breast cancer with ovarian cancer","author":"\u00c7elik","year":"2015","journal-title":"InTech"},{"key":"B3","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/cbdd.13672","article-title":"Common cancer biomarkers of breast and ovarian types identified through artificial intelligence","volume":"96","author":"Pawar","year":"2020","journal-title":"Chem Biol Drug Des"},{"key":"B4","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12935-020-01276-x","article-title":"Early diagnosis of breast and ovarian cancers by body fluids circulating tumor-derived exosomes","volume":"20","author":"Norouzi-Barough","year":"2020","journal-title":"Cancer Cell Int"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e1942","DOI":"10.7717\/peerj-cs.1942","article-title":"Uncovering hidden genetic risk factors for breast and ovarian cancers in BRCA-negative women: a machine learning approach in the Saudi population","volume":"10","author":"Alganmi","year":"2024","journal-title":"PeerJ Comput Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26062716","article-title":"The role of the tumor microenvironment (TME) in advancing cancer therapies: immune system interactions, tumor-infiltrating lymphocytes (TILs), and the role of exosomes and inflammasomes","volume":"26","author":"Erasha","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217385","article-title":"Tumor microenvironment: Nurturing cancer cells for immunoevasion and druggable vulnerabilities for cancer immunotherapy","volume":"611","author":"Yu","year":"2024","journal-title":"Cancer Lett"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.823842","article-title":"Systemic immune dysregulation in early breast cancer is associated with decreased plasma levels of both soluble co-inhibitory and co-stimulatory immune checkpoint molecules","volume":"13","author":"Rapoport","year":"2022","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1097309","article-title":"Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recovery of CD27, CD28, CD40, CD80, ICOS and GITR and substantially increased levels of PD-L1, LAG-3 and TIM-3","volume":"13","author":"Rapoport","year":"2023","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2217\/imt.11.20","article-title":"Immunity and immune suppression in human ovarian cancer","volume":"3","author":"Preston","year":"2011","journal-title":"Immunotherapy"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2022.156051","article-title":"Identification of two theranostic biomarker panels for epithelial ovarian cancer","volume":"161","author":"Habel","year":"2023","journal-title":"Cytokine"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.05.065","article-title":"Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study","volume":"175","author":"Colombo","year":"2023","journal-title":"Gynecol Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-025-02694-5","article-title":"Transforming cancer screening: the potential of multi-cancer early detection (MCED) technologies","volume":"30","author":"Imai","year":"2025","journal-title":"Int J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/app15137018","article-title":"Common molecular mechanisms and biomarkers in breast, colon and ovarian cancer","volume":"15","author":"Garc\u00eda-Ca\u00f1izares","year":"2025","journal-title":"Appl Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310683","article-title":"Deciphering common traits of breast and ovarian cancer stem cells and possible therapeutic approaches","volume":"24","author":"Lu\u010di\u0107","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1388","article-title":"Cancer and the chemokine network","volume":"4","author":"Balkwill","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32030143","article-title":"Breast cancer and tumor microenvironment: the crucial role of immune cells","volume":"32","author":"Moura","year":"2025","journal-title":"Curr Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.585354","article-title":"A review of the progress and challenges of developing a vaccine for COVID-19","volume":"11","author":"Sharma","year":"2020","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1426","article-title":"Chemokines in tumor progression and metastasis","volume":"4","author":"Sarvaiya","year":"2013","journal-title":"Oncotarget"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175586","article-title":"The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF","volume":"949","author":"Ghalehbandi","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189374","article-title":"The VEGF\/VEGFR2 system in ovarian cancer: From functional to pharmacological significance","volume":"1880","author":"Grillo","year":"2025","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s43856-025-00945-0","article-title":"Deep plasma proteomics identifies and validates an eight-protein biomarker panel that separate benign from Malignant tumors in ovarian cancer","volume":"5","author":"Moskov","year":"2025","journal-title":"Commun Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2019.e02826","article-title":"Multi-biomarker panel signature as the key to diagnosis of ovarian cancer","volume":"5","author":"Muinao","year":"2019","journal-title":"Heliyon"},{"key":"B24","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1186\/s12967-025-06508-0","article-title":"Role of tumor microenvironment in ovarian cancer metastasis and clinical advancements","volume":"23","author":"Wang","year":"2025","journal-title":"J Transl Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1369\/0022155411428469","article-title":"Breast and ovarian cancers: a survey and possible roles for the cell surface heparan sulfate proteoglycans","volume":"60","author":"Yoneda","year":"2012","journal-title":"J Histochem Cytochem"},{"key":"B26","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s40001-024-01711-z","article-title":"The paradoxical role of cytokines and chemokines at the tumor microenvironment: a comprehensive review","volume":"29","author":"Abdul-Rahman","year":"2024","journal-title":"Eur J Med Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.622643","article-title":"Immune-inhibitory gene expression is positively correlated with overall immune activity and predicts increased survival probability of cervical and head and neck cancer patients","volume":"8","author":"Budhwani","year":"2021","journal-title":"Front Mol Biosci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/849720","article-title":"The role of chemokines in breast cancer pathology and its possible use as therapeutic targets","volume":"2014","author":"Palacios-Arreola","year":"2014","journal-title":"J Immunol Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/cells13151267","article-title":"Soluble CD40 ligand as a promising biomarker in cancer diagnosis","volume":"13","author":"Pazoki","year":"2024","journal-title":"Cells"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.82317","article-title":"CXCL12-CXCR4\/CXCR7 axis in cancer: from mechanisms to clinical applications","volume":"19","author":"Yang","year":"2023","journal-title":"Int J Biol Sci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12103071","article-title":"The signaling duo CXCL12 and CXCR4: chemokine fuel for breast cancer tumorigenesis","volume":"12","author":"Zieli\u0144ska","year":"2020","journal-title":"Cancers"},{"key":"B32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13053-024-00291-7","article-title":"Blood molybdenum level as a marker of cancer risk on BRCA1 carriers","volume":"22","author":"Matuszczak","year":"2024","journal-title":"Hereditary Cancer Clin Pract"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1741582\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:28:14Z","timestamp":1773923294000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1741582\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":32,"alternative-id":["10.3389\/fimmu.2026.1741582"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1741582","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"article-number":"1741582"}}